Celebrating women leading the business of life science innovation in metro New York and beyond
  • Home
  • About
  • Resources
    • Investment Firms
    • Incubators / Accelerators
    • Women’s Network
  • Metro NYC Events
Menu
  • Home
  • About
  • Resources
    • Investment Firms
    • Incubators / Accelerators
    • Women’s Network
  • Metro NYC Events
  • Home
  • About
  • Resources
    • Investment Firms
    • Incubators / Accelerators
    • Women’s Network
  • Metro NYC Events
  • Home
  • About
  • Resources
    • Investment Firms
    • Incubators / Accelerators
    • Women’s Network
  • Metro NYC Events
Home»Press Release»Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Press Release

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy

Biotech MetropolitanBy Biotech MetropolitanAugust 12, 2019Updated:June 13, 2020No Comments0 Views
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRock Therapeutics to continue to operate as an independent company

Berlin/Cambridge, Massachusetts, August 8, 2019 – Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform.

Following a 2016 joint venture with Versant Ventures to establish BlueRock Therapeutics, Bayer will acquire the remaining stake for approximately USD 240 million in cash to be paid upfront at closing and an additional USD 360 million payable upon achievement of pre-defined development milestones. With Bayer currently holding 40.8 percent stake, the investment corresponds to a total company value of BlueRock Therapeutics of approximately USD 1 billion. The closing of the transaction is expected during the third quarter of 2019 READ MORE AT BAYER…

Author

Biotech Metropolitan
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Biotech Metropolitan

    Related Posts

    Goodwin Welcomes Life Sciences….

    September 17, 2019

    Rgenix Names Industry Veteran to Chief Medical Officer Role

    September 17, 2019

    Medidata and Mapi Research Trust Collaboration

    September 14, 2019

    Leave A Reply Cancel Reply

    Twitter Instagram

    News

    • World
    • Business
    • Connections
    • Science

    Company

    • Contact Info
    • Media Kits

    Services

    • Newsletters

    Subscribe to Updates

    Get the latest news from Biotech Metropolitan Women.

    Biotech Metropolitan Women ©2018-2022

    • Privacy Policy
    • Terms
    • Accessibility

    Type above and press Enter to search. Press Esc to cancel.